UHealth - University of Miami Health System

E-mail a Friend

Joyce M. Slingerland, M.D., Ph.D.

General Information

Joyce M. Slingerland, M.D., Ph.D.



  • Internal Medicine
  • Hematology/Oncology - Internal Medicine



Clinical Areas

Breast Cancer
Medical oncology of patients with breast cancer with an academic research interest in hormonal and molecular targeted therapies for breast cancer.


  • American Board of Internal Medicine


  • Associate Director, Translational Research
  • Director, Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center
  • Professor of Medicine

Research Interests

Dr. Slingerland's research interests include: breast cancer, molecular mechanisms of signal transduction and hormone effects on cell cycle regulation and breast cancer cell growth, breast cancer stem cells as  targets for therapy and  the role of estrogen receptors in breast cancer.

Dr. Slingerland's career in research has been devoted to translation of mechanistic aspects of cell cycle and hormonal regulation of breast cancer. The Slingerland lab investigates how breast cancer cells escape growth control by antiestrogens and inhibitory cytokines. During her post-doctoral work, Dr. Slingerland made the innovative discovery of a key inhibitor of cell cycle progression, p27. Her lab has investigated how p27 is regulated by hormones and mitogenic and growth inhibitory factors in normal and cancer cells. Slingerland et al. demonstrated that p27 levels are reduced in up to 60 % of common human breast and other cancers in association with poor patient prognosis. Dr. Slingerland showed that the growth arrest by inhibitory cytokines such as TGF-b and antiestrogens in breast cancer requires the cdk inhibitors p21 and p27. She showed that constitutive signaling via Her2. Src and MAPK activation deregulates p27 function causing Tamoxifen resistance in breast cancer. She and others demonstrated that a major mechanism of breast and other human cancer progression involves loss or inactivation of p27 through increased p27 degradation, its cytoplasmic mislocalization or sequestration in aberrant protein complexes. Ongoing research addresses how signaling via the phospho-inositol 3'kinase (PI3K) and Ras/Src/Raf/MAPK pathway modulates p27 phosphorylation and function. The consequences of pathway activation and specific effectors that modulate p27 phosphorylation and function are under investigation. An additional research focus in the Slingerland lab addresses how cross talk between liganded ER and receptor tyrosine kinases and Src signal transduction pathways may link transcriptional activity of the ER to its proteolytic degradation. Dr. Slingerland's research laboratory continues to investigate mechanisms regulating the cell cycle, antiestrogen resistance and estrogen receptor regulation in normal and malignant breast cells. Recently, she has initiated new clinical trials of molecular targeted therapies to reverse antiestrogen resistance.


  • Sun J, Zhou W, Nawaz Z, Slingerland JM. (2011) Cross Talk between ERa and Src signaling and its relevance to ER status and hormone responsiveness. Advances in Rapid Sex-Steroid Action: New Challenges and New Chances in Breast and Prostate Cancers. Editors: G. Castoria & A. Migliaccio, Springer, New York, pp. 61-78.
  • Donovan J, Slingerland JM, Tannock I. (2004) Control of cell proliferation. In: 4rd Edition of Basic Science of Oncology. Editors: Ian Tannock and R.P. Hill, McGraw-Hill, New York, Chapter 10
  • Slingerland JM, Tannock I. (1998) Control of cell proliferation and cell death. In: 3rd Edition of Basic Science of Oncology. Editors: Ian Tannock and R.P. Hill, McGraw-Hill, New York, Chapter 7, pp. 134-165
  • Slingerland JM, Pagano M. (1998) Regulation of the cell cycle by the ubiquitin pathway. In: Cell Cycle Control. Part of the results and problems in cell differentiation series. Springer Verlag Publishers (Editor: M. Pagano), Chapter 6, pp. 133-147.
  • Slingerland JM, Greisser H, Mak TW, Minden MD. (1988) The structure and function of the T-cell antigen receptor in human malignancies. In: T.W. Mak (Ed.), The T-cell Receptor, New York: Plenum Press.


Senior Clinician-Research Award
Honorary Member
Canada Research Chair in Molecular Medicine
Clinician Scientist Award
Career Development Award
Young Clinician-Research Award
Early Career Development Award
Senior Postdoctoral Research Fellowship Award
Post-MD Research Fellowship Award
1924 War Service Scholarship
University Scholar


1992 Ph.D.
University of Toronto, Department of Medical Biophysics
1988 Fellowship
Princess Margaret Hospital, Division of Oncology
1987 Chief Resident
The Wellesley Hospital
1986 Residency
Princess Margaret Hospital
1985 Resident II
Toronto Hospital (General Division), Internal Medicine
1984 Straight Internship
Toronto Hospital, (General Division), Internal Medicine
1983 M.D.
University of Toronto
1977 Diplome d’Etudes Collegiales
College de Ste-Foy


Joyce Slingerland, MD, FRCP(C), Ph.D., Director, Braman Family Breast Cancer Institute at the University of Miami Sylvester Comprehensive Cancer Center (UMSCCC).
A native of Canada, Dr. Slingerland received her M.D. from the University of Toronto in 1983, followed by a Fellowship in Internal Medicine with the Royal College of Physicians and Surgeons in Canada. In 1987, she was certified by the American Board in Internal Medicine and in Medical Oncology by the Royal College of Physicians and Surgeons. In August of 2002, Dr. Slingerland came to the University of Miami School of Medicine as the Director of the Braman Breast Cancer Institute, Sylvester Comprehensive Cancer Center where she is working to expand and coordinate research efforts on breast cancer from many disciplines. Dr. Slingerland is also Professor of Medicine with a graduate appointment in the Department of Biochemistry and
Molecular Biology at the University of Miami, as well as a member of the senior leadership of the UMSCCC and Co-Program Leader of the UMSCCC's Molecular Oncology and Experimental Therapeutics Program. Dr. Slingerland continues her medical practice devoted entirely to breast cancer patients
at the Sylvester Comprehensive Cancer Center and the Jackson Memorial Hospital. She has published over 50 articles and reviews in addition to
several book chapters and has received numerous awards. The Slingerland's lab has been funded by the Canadian NCI's Breast Cancer Research Initiative and by the DOD Breast Cancer Research Program and now the US NCI. Her research has provided insights on how cancers escape negative growth controls. Dr. Slingerland has made the innovative discovery of the cell cycle inhibitor, p27, and showed that p27 deregulation is prognostic of
poor patient outcome and leads to antiestrogen resistance in estrogen receptor positive breast cancers.


E-mail a Friend